glp 1 receptor agonists are contraindicated in glp-1_analogs [TUSOM Glucagon-Like Peptide-1 Receptor Agonist Use
Description
Synergistic anti-tumor effects of liraglutide, a glucagon-like peptide-1 receptor agonist, along with docetaxel on LNCaP prostate cancer cell line
7 For patients who stop treatment early, weight regain is common
The future of GLP-1 insurance coverage The current coverage contraction is not necessarily permanent
They cause weight loss at a scale hitherto unknown in the modern medical era
doi: 10.1016/j.molmet.2024.102019
Lifescan Diabetes Institute website
